The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review.

IF 4.5 2区医学 Q1 ONCOLOGY

Cancers Pub Date : 2025-03-20 DOI:10.3390/cancers17061049

David Armany, Lequang Vo, Duncan Self, Sriskanthan Baskaranathan, Tania Hossack, Simon Bariol, David Ende, Henry Hyunshik Woo

{"title":"The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review.","authors":"David Armany, Lequang Vo, Duncan Self, Sriskanthan Baskaranathan, Tania Hossack, Simon Bariol, David Ende, Henry Hyunshik Woo","doi":"10.3390/cancers17061049","DOIUrl":null,"url":null,"abstract":"Background: To determine and review the currently available literature behind the staging capabilities of 18F-PSMA-1007 PET/CT in the setting of initial staging and detection of recurrent disease for patients with prostate cancer. Prostate cancer (PCa), one of the most diagnosed malignancies affecting adult men worldwide, requires accurate staging and early detection of recurrent disease to guide treatment decisions and improve oncological outcomes. 18F-PSMA-1007 PET/CT is a novel radiotracer with favorable imaging characteristics suggesting an important role within the Prostate Cancer management landscape.Methods: The Arksey and O'Malley Framework was used to guide this review. PubMed/MEDLINE, EMBASE, EBSCO, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were used, and relevant titles were screened for eligibility.Results: 404 database results were returned; 343 titles were excluded due to irrelevance and duplicates. A total of 61 papers were included for title and abstract review with a subsequent 26 excluded due to not meeting the inclusion criteria. A total of 35 papers proceeded to full-text review and 35 papers were included in this review. Evidence was grouped under three major themes: (1) The role of 18F-PSMA-1007 PET/CT in Initial staging; (2) The role of 18F-PSMA-1007 PET/CT in the detection of recurrent Prostate Cancer and (3) The Role of 18F-PSMA-1007 PET/CT in Salvage Therapy. The findings suggest 18F-PSMA-1007 PET/CT has superior diagnostic accuracy and sensitivity for the initial staging of prostate cancer compared with conventional imaging and other commonly used radiotracers. Strengths included the detection of pelvic and locoregional disease. Limitations included poor specificity for the detection of bone lesions, inconsistent urinary excretion patterns, and high inter-reader variability.Conclusions: 18F-PSMA-1007 PET/CT demonstrates superior diagnostic accuracy and sensitivity in both initial staging and detection of prostate cancer recurrence; however, it is limited by poor specificity for bone lesions and inconsistent urinary excretion patterns. Prospective multicenter trials are required to clearly delineate its role in the initial staging of prostate cancer and detection of recurrent disease.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941518/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17061049","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To determine and review the currently available literature behind the staging capabilities of 18F-PSMA-1007 PET/CT in the setting of initial staging and detection of recurrent disease for patients with prostate cancer. Prostate cancer (PCa), one of the most diagnosed malignancies affecting adult men worldwide, requires accurate staging and early detection of recurrent disease to guide treatment decisions and improve oncological outcomes. 18F-PSMA-1007 PET/CT is a novel radiotracer with favorable imaging characteristics suggesting an important role within the Prostate Cancer management landscape.

Methods: The Arksey and O'Malley Framework was used to guide this review. PubMed/MEDLINE, EMBASE, EBSCO, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were used, and relevant titles were screened for eligibility.

Results: 404 database results were returned; 343 titles were excluded due to irrelevance and duplicates. A total of 61 papers were included for title and abstract review with a subsequent 26 excluded due to not meeting the inclusion criteria. A total of 35 papers proceeded to full-text review and 35 papers were included in this review. Evidence was grouped under three major themes: (1) The role of 18F-PSMA-1007 PET/CT in Initial staging; (2) The role of 18F-PSMA-1007 PET/CT in the detection of recurrent Prostate Cancer and (3) The Role of 18F-PSMA-1007 PET/CT in Salvage Therapy. The findings suggest 18F-PSMA-1007 PET/CT has superior diagnostic accuracy and sensitivity for the initial staging of prostate cancer compared with conventional imaging and other commonly used radiotracers. Strengths included the detection of pelvic and locoregional disease. Limitations included poor specificity for the detection of bone lesions, inconsistent urinary excretion patterns, and high inter-reader variability.

Conclusions: 18F-PSMA-1007 PET/CT demonstrates superior diagnostic accuracy and sensitivity in both initial staging and detection of prostate cancer recurrence; however, it is limited by poor specificity for bone lesions and inconsistent urinary excretion patterns. Prospective multicenter trials are required to clearly delineate its role in the initial staging of prostate cancer and detection of recurrent disease.

查看原文本刊更多论文

背景：确定 18F-PSMA-1007 PET/CT 在对前列腺癌患者进行初步分期和复发疾病检测方面的分期能力，并对其背后的现有文献进行回顾。前列腺癌（PCa）是全球成年男性发病率最高的恶性肿瘤之一，需要准确的分期和复发疾病的早期检测来指导治疗决策和改善肿瘤治疗效果。18F-PSMA-1007 PET/CT 是一种新型放射性示踪剂，具有良好的成像特性，在前列腺癌的治疗中发挥着重要作用：方法：本综述采用 Arksey 和 O'Malley 框架。采用 PubMed/MEDLINE、EMBASE、EBSCO 和 Cochrane 对照试验中央登记册 (CENTRAL) 数据库，并对相关标题进行资格筛选：结果：共检索到 404 条数据库结果，其中 343 条因不相关和重复而被排除。共有 61 篇论文被纳入标题和摘要审查，其中 26 篇因不符合纳入标准而被排除。共有 35 篇论文进行了全文审阅，35 篇论文被纳入本综述。证据分为三大主题：（1）18F-PSMA-1007 PET/CT 在初始分期中的作用；（2）18F-PSMA-1007 PET/CT 在检测复发性前列腺癌中的作用；（3）18F-PSMA-1007 PET/CT 在挽救治疗中的作用。研究结果表明，与传统成像和其他常用放射性核素相比，18F-PSMA-1007 PET/CT 在前列腺癌初步分期方面具有更高的诊断准确性和灵敏度。优点包括能发现盆腔和局部区域疾病。局限性包括检测骨病变的特异性较差、尿液排泄模式不一致以及阅片师之间的差异较大：结论：18F-PSMA-1007 PET/CT 在前列腺癌的初始分期和复发检测方面都显示出卓越的诊断准确性和灵敏度，但由于对骨病变的特异性差和尿液排泄模式不一致而受到限制。需要进行前瞻性多中心试验，以明确其在前列腺癌初始分期和检测复发疾病中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.